We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-6.18%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$20.6B
AUM Growth
-$2.22B
Cap. Flow
+$62.6M
Cap. Flow %
0.3%
Top 10 Hldgs %
83.49%
Holding
126
New
5
Increased
17
Reduced
8
Closed
5

Top Buys

Rank Stock Value
1
TRDA icon
Entrada Therapeutics
TRDA
+$114M
2
INCY icon
Incyte
INCY
+$108M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$46.7M
4
TSVT
2seventy bio
TSVT
+$26M
5
TVTX icon
Travere Therapeutics
TVTX
+$17.7M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$66.1M
2
FLGT icon
Fulgent Genetics
FLGT
+$17.5M
3
BLUE
bluebird bio
BLUE
+$16M
4
MIRM icon
Mirum Pharmaceuticals
MIRM
+$12.9M
5
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$11.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.19%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XENE icon
51
Xenon Pharmaceuticals
XENE
$6.1B
$23.5M 0.11%
751,639
– –
DBVT
52
DBV Technologies
DBVT
$813M
$23.4M 0.11%
1,461,426
– –
AXSM icon
53
Axsome Therapeutics
AXSM
$11.7B
$23.1M 0.11%
610,970
+71,913
+13% +$2.65M
JBIO
54
Jade Biosciences
JBIO
$1.18B
$21.6M 0.11%
52,337
+5,132
+11% +$2.6M
TSVT
55
DELISTED
2seventy bio
TSVT
$21.4M 0.1%
+833,236
New +$26M
FLGT icon
56
Fulgent Genetics
FLGT
$558M
$20.3M 0.1%
201,444
-199,572
-50% -$17.5M
NGNE icon
57
Neurogene
NGNE
$672M
$18.4M 0.09%
191,087
– –
OTIC
58
DELISTED
Otonomy, Inc.
OTIC
$16.3M 0.08%
7,844,692
+150,654
+2% +$310K
SYRE icon
59
Spyre Therapeutics
SYRE
$8.5B
$16.2M 0.08%
136,404
– –
BCAB icon
60
BioAtla
BCAB
$5.34M
$16.2M 0.08%
16,500
– –
SRZN icon
61
Surrozen
SRZN
$223M
$16.1M 0.08%
166,667
– –
REPL icon
62
Replimune Group
REPL
$454M
$16.1M 0.08%
593,395
+439,883
+287% +$13.2M
DICE
63
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$14.9M 0.07%
588,235
– –
ANAB icon
64
AnaptysBio
ANAB
$1.54B
$14.8M 0.07%
427,179
– –
AFMD
65
DELISTED
Affimed
AFMD
$14.6M 0.07%
265,317
+248,856
+1,512% +$15.4M
ACHL
66
DELISTED
Achilles Therapeutics
ACHL
$13M 0.06%
2,591,366
– –
CNTA
67
DELISTED
Centessa Pharmaceuticals
CNTA
$12.7M 0.06%
1,127,273
– –
TCDA
68
DELISTED
Tricida, Inc. Common Stock
TCDA
$12.3M 0.06%
1,285,014
+247,582
+24% +$1.6M
RLMD icon
69
Relmada Therapeutics
RLMD
$540M
$11.2M 0.05%
495,113
+294,117
+146% +$6.54M
SRPT icon
70
Sarepta Therapeutics
SRPT
$1.64B
$11.1M 0.05%
+123,456
New +$10.6M
BCEL
71
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$10.7M 0.05%
3,532,760
– –
LONA
72
LeonaBio Inc
LONA
$66.1M
$10.5M 0.05%
80,637
– –
ALT icon
73
Altimmune
ALT
$568M
$9.82M 0.05%
1,072,038
– –
CYT
74
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$9.24M 0.05%
812,640
– –
KRTX
75
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$9.17M 0.04%
69,966
– –
1 2
3
4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2021 Portfolio in Review

As of Q4 2021, Baker Bros. Advisors held 126 positions worth $20.6B, down 9.7% from $22.8B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Baker Bros. Advisors's Q4 2021 filing shows 5 new, 17 increased, 8 reduced and 5 closed positions. Its largest new stake was Entrada Therapeutics: 4,704,419 shares worth $80.5M. The largest sale was Seagen Inc. Common Stock, an estimated $66.1M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q4 2021 buy was Entrada Therapeutics: 4,704,419 shares worth $80.5M.
  • Baker Bros. Advisors added most to Incyte in Q4 2021, an estimated $108M increase.
  • Baker Bros. Advisors's biggest Q4 2021 reduction was Seagen Inc. Common Stock, cutting an estimated $66.1M.
  • Baker Bros. Advisors fully exited Mirum Pharmaceuticals in Q4 2021, selling an estimated $12.9M.
  • Baker Bros. Advisors's ten largest holdings make up 83% of its $20.6B portfolio in Q4 2021.
  • Baker Bros. Advisors opened 5 new positions and closed 5 in Q4 2021.
  • Baker Bros. Advisors's portfolio value fell 9.7% quarter-over-quarter to $20.6B.

Based on Baker Bros. Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.